Living Cell Technologies has appointed Dr. Belinda Di Bartolo as Chief Operating Officer. Dr. Di Bartolo will lead the planning and preparations for the third clinical trial of NTCELL in Parkinson's disease. Dr. Di Bartolo has 18 years' experience in health and medical research. She has a clear understanding of the translational pathway of research as well as knowledge of the regulatory processes, with experience in ethics and governance committees. Dr. Di Bartolo, who is based in Sydney, has outstanding leadership and relationship skills and a fundamental passion for medical research. Prior to joining LCT, Dr. Di Bartolo was a research fellow at the Kolling Institute at the University of Sydney, NSW. She previously held research roles at SAHMRI, The Heart Research Institute and the University of New South Wales, NSW.